Literature DB >> 19337569

Models of ovarian cancer metastasis: Murine models.

Sanja Sale1, Sandra Orsulic.   

Abstract

Mice have mainly been used in ovarian cancer research as immunodeficient hosts for cell lines derived from the primary tumors and ascites of ovarian cancer patients. These xenograft models have provided a valuable system for pre-clinical trials, however, the genetic complexity of human tumors has precluded the understanding of key events that drive metastatic dissemination. Recently developed immunocompetent, genetically defined mouse models of epithelial ovarian cancer represent significant improvements in the modeling of metastatic disease.

Entities:  

Year:  2006        PMID： 19337569      PMCID： PMC2662599          DOI： 10.1016/j.ddmod.2006.05.006

Source DB:  PubMed          Journal:  Drug Discov Today Dis Models        ISSN： 1740-6757


  23 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.

Authors:  Daniela M Dinulescu; Tan A Ince; Bradley J Quade; Sarah A Shafer; Denise Crowley; Tyler Jacks
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

3.  Radiation-induced apoptosis in human ovarian carcinoma cells growing as a monolayer and as multicell spheroids.

Authors:  I V Filippovich; N I Sorokina; N Robillard; J F Chatal
Journal:  Int J Cancer       Date:  1997-09-04       Impact factor: 7.396

4.  Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis.

Authors:  M J Gardner; J B Catterall; L M Jones; G A Turner
Journal:  Clin Exp Metastasis       Date:  1996-09       Impact factor: 5.150

Review 5.  Models of ovarian cancer--are we there yet?

Authors:  Kenneth Garson; Tanya J Shaw; Katherine V Clark; De-Sheng Yao; Barbara C Vanderhyden
Journal:  Mol Cell Endocrinol       Date:  2005-07-15       Impact factor: 4.102

6.  Production of stromal cell-derived factor 1 by mesothelial cells and effects of this chemokine on peritoneal B lymphocytes.

Authors:  A Foussat; K Balabanian; A Amara; L Bouchet-Delbos; I Durand-Gasselin; F Baleux; J Couderc; P Galanaud; D Emilie
Journal:  Eur J Immunol       Date:  2001-02       Impact factor: 5.532

7.  Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids.

Authors:  S Makhija; D D Taylor; R K Gibb; C Gerçel-Taylor
Journal:  Int J Oncol       Date:  1999-03       Impact factor: 5.650

8.  Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions.

Authors:  H J Allen; C Porter; M Gamarra; M S Piver; E A Johnson
Journal:  Exp Cell Biol       Date:  1987

9.  Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry.

Authors:  Travis W Young; Fang C Mei; Gong Yang; Jennifer A Thompson-Lanza; Jinsong Liu; Xiaodong Cheng
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

Review 10.  Host genetics and tumour metastasis.

Authors:  K W Hunter
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640
View more
  14 in total

1.  Hippo pathway effector Yap is an ovarian cancer oncogene.

Authors:  Chad A Hall; Runsheng Wang; Jiangyong Miao; Esther Oliva; Xiaoyun Shen; Thomas Wheeler; Susan G Hilsenbeck; Sandra Orsulic; Scott Goode
Journal:  Cancer Res       Date:  2010-10-14       Impact factor: 12.701

2.  Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment.

Authors:  Adrianne Wallace-Povirk; Lisa Rubinsak; Agnes Malysa; Sijana H Dzinic; Manasa Ravindra; Mathew Schneider; James Glassbrook; Carrie O'Connor; Zhanjun Hou; Seongho Kim; Jessica Back; Lisa Polin; Robert T Morris; Aleem Gangjee; Heather Gibson; Larry H Matherly
Journal:  Sci Rep       Date:  2022-07-05       Impact factor: 4.996

Review 3.  Molecular and clinical implementations of ovarian cancer mouse avatar models.

Authors:  Amira A Zayed; Sumithra J Mandrekar; Paul Haluska
Journal:  Chin Clin Oncol       Date:  2015-09

Review 4.  Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.

Authors:  Clare L Scott; Marc A Becker; Paul Haluska; Goli Samimi
Journal:  Front Oncol       Date:  2013-12-04       Impact factor: 6.244

5.  Ovulation and extra-ovarian origin of ovarian cancer.

Authors:  Yang Yang-Hartwich; Marta Gurrea-Soteras; Natalia Sumi; Won Duk Joo; Jennie C Holmberg; Vinicius Craveiro; Ayesha B Alvero; Gil Mor
Journal:  Sci Rep       Date:  2014-08-19       Impact factor: 4.379

6.  NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.

Authors:  Rosa Mistica C Ignacio; Syeda M Kabir; Eun-Sook Lee; Samuel E Adunyah; Deok-Soo Son
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

7.  Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer.

Authors:  Xiaoguang Li; Yu Zhou; Yanling Liu; Xu Zhang; Tao Chen; Kerong Chen; Qian Ba; Jingquan Li; Hong Liu; Hui Wang
Journal:  EBioMedicine       Date:  2016-11-23       Impact factor: 8.143

8.  The Exocrine Differentiation and Proliferation Factor (EXDPF) Gene Promotes Ovarian Cancer Tumorigenesis by Up-Regulating DNA Replication Pathway.

Authors:  Yangjiong Xiao; Yunxin Lai; Yang Yu; Pengcheng Jiang; Yuhong Li; Chao Wang; Rong Zhang
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

9.  Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis.

Authors:  Noor A Lokman; Alison S F Elder; Carmela Ricciardelli; Martin K Oehler
Journal:  Int J Mol Sci       Date:  2012-08-10       Impact factor: 6.208

10.  Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms.

Authors:  Paul Michael Jones; Ronny Drapkin
Journal:  Front Oncol       Date:  2013-08-26       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.